Also trades as: 0QF.F (FSX) · $vol 6M
MRNA NASDAQ
Moderna, Inc.
1W: -12.4%
1M: -0.0%
3M: +256.3%
YTD: +374.0%
1Y: +681.3%
3Y: +76.3%
5Y: -52.6%
$207.88
+9.04 (+4.54%)
After Hours: $207.50 (-0.38, -0.19%)
Weekly Expected Move ±15.2%
$139
$170
$200
$231
$261
Credit Risk of going bust: higher than 69% of companies Debt: 1.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.44 (down 99.8%), Moderna, Inc. would be worth roughly what it owes.
Total debt $1.29B against a stock market value of $79.39B.
Distance to default 3.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $347.5M (short-term plus half of long-term), stock volatility 132.3%; Altman Z'' 3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.44 (down 99.8%), Moderna, Inc. would be worth roughly what it owes.
Total debt $1.29B against a stock market value of $79.39B.
Distance to default 3.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $347.5M (short-term plus half of long-term), stock volatility 132.3%; Altman Z'' 3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
2 bullish
0 neutral
2 bearish
Articles (24h)
4
Hourly Sentiment (24h)
-0.14
Neutral
8 bullish
6 neutral
12 bearish
Articles (7d)
26
Daily Sentiment (7 Days)
Articles (100)
Moderna falls as William Blair is latest to downgrade on valuation
U.S. equities trend higher as FOMC rate decision and big tech earnings loom
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
Moderna CEO Bancel sees other cancer indications for melanoma vaccine
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?
At a glance: stocks gapping down premarket
EULAV Asset Management Acquires 9,727 Shares of Moderna, Inc. $MRNA
Moderna, Inc. $MRNA Shares Sold by IFP Advisors Inc
$MRNA opening at what price?
Trending stocks this week as markets navigate AI concerns, geopolitical tensions
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Breakfast News: A Conversation With Moderna’s CEO
5,000 Shares of Moderna, Inc. $MRNA Bought by Credit Capital Investments LLC
Tech stocks weigh on Nasdaq for second week; Roper leads gainers
Analysts weigh in on Moderna's big drop following cancer vaccine results
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
Biggest stock movers Friday: SKHY, MRNA, DECK, and more
The top-performing S&P 500 stocks YTD have shed almost 7% on average
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
Moderna (MRNA) Rises Higher Than Market: Key Facts
S&P 500 Sector Rotation Tracker: Energy takes the wheel as tech hits the brakes
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
$MRNA is stupid
Lilly, METiS ink AI-driven drug delivery deal worth up to $1.1B
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going
Moderna, Inc. $MRNA Shares Sold by Banque Pictet & Cie SA
Moderna retreats 8% amid valuation debate ahead of cancer data
Catalyst Watch: Meta earnings, Kroger event, and Black Monday turns 39
Nasdaq plunges 2% and these 15 names have led the downward decline
Moderna falls ahead of cancer vaccine data next week
Midday Pulse: S&P 500 top intraday losers
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
Moderna rallies despite bearish views ahead of cancer vaccine data
Cedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint
Stocks making big moves after hours: SANM, KEYS, AIZ
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Here's Why Moderna (MRNA) Fell More Than Broader Market
S&P 500 surpasses 1,000 trading days without a new 52-week low
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Notable healthcare headlines for the week: Novavax, Moderna and Becton Dickinson in focus
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?
Why Moderna Stock Surged Today
Moderna gains 14% to set fresh 52-week high
This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street
Catalyst watch: Big bank earnings, CPI, and the Paris Auto Show
Another $600k USD gain on $MRNA (total +1.18M USD gain)
Moderna stock jumps on planned national cancer vaccine effort
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Moderna (NASDAQ:MRNA) Shares Up 8.3% - Here's Why - MarketBeat
Moderna stock fires past 52-week high: what's behind Friday's rally? - TradingView
Moderna Inc Stock (MRNA) Moved Up by 7.63% on Oct 9: A Full Analysis - TradingKey
Learn Why The Bull Case For Moderna Stock Could Change Following COO Appointment - Simply Wall Street
Rep. Maria Elvira Salazar Unloads Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
MRNA Jan 2029 270.000 call (MRNA290119C00270000) interactive stock chart - Yahoo Finance UK
MRNA Jan 2028 190.000 put (MRNA280121P00190000) stock price, news, quote and history - Yahoo Finance UK
Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development
Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?
MRNA Oct 2026 230.000 call (MRNA261030C00230000) stock price, news, quote and history - Yahoo Finance UK
MRNA Jan 2029 100.000 call (MRNA290119C00100000) stock price, news, quote and history - Yahoo Finance UK
MRNA Oct 2026 177.500 call (MRNA261030C00177500) stock price, news, quote and history - Yahoo Finance UK
eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
3 Stocks That Have More Than Doubled the S&P 500’s Return This Year
Company News for Oct 8, 2026
US Stock Market Today: S&P 500 Futures Hold Flat As Trade Deficit Worries Return
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
MRNA Stock Falls Premarket: Citi Turns Bearish On Moderna After Massive 2026 Rally - Stocktwits
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Tempus CEO on How AI Can Save Healthcare
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Wall Street closed in the red as investors focused on yields and the Fed minutes
CPHI 2026: Moderna builds on its COVID-era manufacturing lessons
2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
Tempus AI expands cancer therapy deal with Moderna, Merck
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Dow Jones Futures Fall, Yields Jump After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys
Moderna (MRNA) Could Be 57% Above Fair Value On New COO Appointment
Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?
State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine schedule
25 stocks up more than +100% in 2026 as the S&P 500 hits record high
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
Novavax, Moderna cool as WHO downplays plague-related death in Russia
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares. - Stock Titan
What's next for personalized mRNA cancer vaccines?
Moderna Inc Stock (MRNA) Moved Up by 5.71% on Oct 5: What Investors Need To Know - TradingKey
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds - The Globe and Mail
Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running? - Yahoo Finance
Jim Cramer Says This Stock Could Rise Like Moderna (MRNA) - Yahoo Finance